Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer
Abstract
:1. Introduction
2. Results
2.1. Results from Studies with miR-21 as a Circulating Biomarker
2.2. Results from Studies with Circulating miRNAs as Prognostic for Outcome in CRC Patients
2.3. Results from Studies with Circulating miRNAs as Potentially Predictive Biomarkers in Treatment of CRC
2.4. Normalization Methods
3. Discussion
4. Conclusions
Author Contributions
Conflicts of Interest
References
- Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9–29. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Zhang, K.Y.; Liu, S.M.; Sen, S. Tumor-associated circulating micrornas as biomarkers of cancer. Molecules 2014, 19, 1912–1938. [Google Scholar] [CrossRef] [PubMed]
- Esquela-Kerscher, A.; Slack, F.J. Oncomirs—Micrornas with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269. [Google Scholar] [CrossRef] [PubMed]
- Neerincx, M.; Sie, D.L.; van de Wiel, M.A.; van Grieken, N.C.; Burggraaf, J.D.; Dekker, H.; Eijk, P.P.; Ylstra, B.; Verhoef, C.; Meijer, G.A.; et al. Mir expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis 2015, 4, e170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.; Boultwood, J.; Wainscoat, J.S.; et al. Detection of elevated levels of tumour-associated micrornas in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141, 672–675. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating micrornas as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [Google Scholar] [CrossRef] [PubMed]
- Zen, K.; Zhang, C.Y. Circulating micrornas: A novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 2012, 32, 326–348. [Google Scholar] [CrossRef] [PubMed]
- Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of mrnas and micrornas is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659. [Google Scholar] [CrossRef] [PubMed]
- Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. Micrornas are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423–433. [Google Scholar] [CrossRef] [PubMed]
- Turchinovich, A.; Weiz, L.; Langheinz, A.; Burwinkel, B. Characterization of extracellular circulating microrna. Nucleic Acids Res. 2011, 39, 7223–7233. [Google Scholar] [CrossRef] [PubMed]
- Becker, N.; Lockwood, C.M. Pre-analytical variables in mirna analysis. Clin. Biochem. 2013, 46, 861–868. [Google Scholar] [CrossRef] [PubMed]
- Jarry, J.; Schadendorf, D.; Greenwood, C.; Spatz, A.; van Kempen, L.C. The validity of circulating micrornas in oncology: Five years of challenges and contradictions. Mol. Oncol. 2014, 8, 819–829. [Google Scholar] [CrossRef] [PubMed]
- Slaby, O.; Svoboda, M.; Fabian, P.; Smerdova, T.; Knoflickova, D.; Bednarikova, M.; Nenutil, R.; Vyzula, R. Altered expression of mir-21, mir-31, mir-143 and mir-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72, 397–402. [Google Scholar] [CrossRef] [PubMed]
- Shibuya, H.; Iinuma, H.; Shimada, R.; Horiuchi, A.; Watanabe, T. Clinicopathological and prognostic value of microrna-21 and microrna-155 in colorectal cancer. Oncology 2010, 79, 313–320. [Google Scholar] [CrossRef] [PubMed]
- Hansen, T.F.; Kjaer-Frifeldt, S.; Christensen, R.D.; Morgenthaler, S.; Blondal, T.; Lindebjerg, J.; Sorensen, F.B.; Jakobsen, A. Redefining high-risk patients with stage II colon cancer by risk index and microrna-21: Results from a population-based cohort. Br. J. Cancer 2014, 111, 1285–1292. [Google Scholar] [CrossRef]
- Toiyama, Y.; Takahashi, M.; Hur, K.; Nagasaka, T.; Tanaka, K.; Inoue, Y.; Kusunoki, M.; Boland, C.R.; Goel, A. Serum mir-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst. 2013, 105, 849–859. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.H.; Zhou, Z.G.; Chen, R.; Wang, M.J.; Zhou, B.; Li, Y.; Sun, X.F. Serum mir-21 and mir-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2013, 34, 2175–2181. [Google Scholar] [CrossRef] [PubMed]
- Menendez, P.; Padilla, D.; Villarejo, P.; Palomino, T.; Nieto, P.; Menendez, J.M.; Rodriguez-Montes, J.A. Prognostic implications of serum microrna-21 in colorectal cancer. J. Surg. Oncol. 2013, 108, 369–373. [Google Scholar] [CrossRef]
- Pu, X.X.; Huang, G.L.; Guo, H.Q.; Guo, C.C.; Li, H.; Ye, S.; Ling, S.; Jiang, L.; Tian, Y.; Lin, T.Y. Circulating mir-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010, 25, 1674–1680. [Google Scholar] [CrossRef] [PubMed]
- Monzo, M.; Martinez-Rodenas, F.; Moreno, I.; Navarro, A.; Santasusagna, S.; Macias, I.; Munoz, C.; Tejero, R.; Hernandez, R. Differential mir-21 expression in plasma from mesenteric versus peripheral veins: An observational study of disease-free survival in surgically resected colon cancer patients. Medicine 2015, 94, e145. [Google Scholar] [CrossRef] [PubMed]
- Toiyama, Y.; Hur, K.; Tanaka, K.; Inoue, Y.; Kusunoki, M.; Boland, C.R.; Goel, A. Serum mir-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 2014, 259, 735–743. [Google Scholar] [CrossRef] [PubMed]
- Cheng, H.; Zhang, L.; Cogdell, D.E.; Zheng, H.; Schetter, A.J.; Nykter, M.; Harris, C.C.; Chen, K.; Hamilton, S.R.; Zhang, W. Circulating plasma mir-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011, 6, e17745. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Huang, S.K.; Zhao, M.; Yang, M.; Zhong, J.L.; Gu, Y.Y.; Peng, H.; Che, Y.Q.; Huang, C.Z. Identification of a circulating microrna signature for colorectal cancer detection. PLoS ONE 2014, 9, e87451. [Google Scholar] [CrossRef] [PubMed]
- Lv, Z.C.; Fan, Y.S.; Chen, H.B.; Zhao, D.W. Investigation of microrna-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2015, 36, 1619–1625. [Google Scholar] [CrossRef] [PubMed]
- Jinushi, T.; Shibayama, Y.; Kinoshita, I.; Oizumi, S.; Jinushi, M.; Aota, T.; Takahashi, T.; Horita, S.; Dosaka-Akita, H.; Iseki, K. Low expression levels of microrna-124-5p correlated with poor prognosis in colorectal cancer via targeting of smc4. Cancer Med. 2014, 3, 1544–1552. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Xia, H.W.; Ge, X.J.; Zhang, Y.C.; Tang, Q.L.; Bi, F. Serum mir-19a predicts resistance to folfox chemotherapy in advanced colorectal cancer cases. Asian Pac. J. Cancer Prev. 2013, 14, 7421–7426. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Zhang, K.; Bi, M.; Jiao, X.; Zhang, D.; Dong, Q. Circulating microrna expressions in colorectal cancer as predictors of response to chemotherapy. Anti-Cancer Drugs 2014, 25, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Kjersem, J.B.; Ikdahl, T.; Lingjaerde, O.C.; Guren, T.; Tveit, K.M.; Kure, E.H. Plasma micrornas predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol. Oncol. 2014, 8, 59–67. [Google Scholar] [CrossRef] [PubMed]
- Hansen, T.F.; Carlsen, A.L.; Heegaard, N.H.; Sorensen, F.B.; Jakobsen, A. Changes in circulating microrna-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br. J. Cancer 2015, 112, 624–629. [Google Scholar] [CrossRef] [PubMed]
- Schou, J.V.; Rossi, S.; Jensen, B.V.; Nielsen, D.L.; Pfeiffer, P.; Hogdall, E.; Yilmaz, M.; Tejpar, S.; Delorenzi, M.; Kruhoffer, M.; et al. Mir-345 in metastatic colorectal cancer: A non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS ONE 2014, 9, e99886. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Wang, W.; Zhang, Y.; Chen, Y.; Hu, T. Predicting distant metastasis and chemoresistance using plasma mirnas. Med. Oncol. 2014, 31, 799. [Google Scholar] [CrossRef] [PubMed]
- Yuan, D.; Li, K.; Zhu, K.; Yan, R.; Dang, C. Plasma mir-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 2015, 16, 268–275. [Google Scholar] [CrossRef] [PubMed]
- Leidner, R.S.; Li, L.; Thompson, C.L. Dampening enthusiasm for circulating microrna in breast cancer. PLoS ONE 2013, 8, e57841. [Google Scholar] [CrossRef] [PubMed]
- Meisgen, F.; Xu, N.; Wei, T.; Janson, P.C.; Obad, S.; Broom, O.; Nagy, N.; Kauppinen, S.; Kemeny, L.; Stahle, M.; et al. Mir-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp. Dermatol. 2012, 21, 312–314. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, K.; Fassan, M.; Mescoli, C.; Pizzi, M.; Balistreri, M.; Albertoni, L.; Pucciarelli, S.; Scarpa, M.; Sturniolo, G.C.; Angriman, I.; et al. Pdcd4/mir-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch. 2013, 462, 57–63. [Google Scholar] [CrossRef] [PubMed]
- Chim, S.S.; Shing, T.K.; Hung, E.C.; Leung, T.Y.; Lau, T.K.; Chiu, R.W.; Lo, Y.M. Detection and characterization of placental micrornas in maternal plasma. Clin. Chem. 2008, 54, 482–490. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Ge, Q.; Guo, L.; Lu, Z. Maternal plasma mirnas expression in preeclamptic pregnancies. BioMed. Res. Int. 2013, 2013, 970265. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Tam, L.S.; Li, E.K.; Kwan, B.C.; Chow, K.M.; Luk, C.C.; Li, P.K.; Szeto, C.C. Serum and urinary free microrna level in patients with systemic lupus erythematosus. Lupus 2011, 20, 493–500. [Google Scholar] [CrossRef] [PubMed]
- Gonzales, J.C.; Fink, L.M.; Goodman, O.B., Jr.; Symanowski, J.T.; Vogelzang, N.J.; Ward, D.C. Comparison of circulating microrna 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 2011, 9, 39–45. [Google Scholar] [CrossRef] [PubMed]
- Diaz, T.; Tejero, R.; Moreno, I.; Ferrer, G.; Cordeiro, A.; Artells, R.; Navarro, A.; Hernandez, R.; Tapia, G.; Monzo, M. Role of mir-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J. Surg. Oncol. 2014, 109, 676–683. [Google Scholar] [CrossRef] [PubMed]
- Mirbase. Available online: Http://www.Mirbase.Org (accessed on June 2014).
- Pritchard, C.C.; Kroh, E.; Wood, B.; Arroyo, J.D.; Dougherty, K.J.; Miyaji, M.M.; Tait, J.F.; Tewari, M. Blood cell origin of circulating micrornas: A cautionary note for cancer biomarker studies. Cancer Prev. Res. 2012, 5, 492–497. [Google Scholar] [CrossRef] [PubMed]
- Cheng, H.H.; Yi, H.S.; Kim, Y.; Kroh, E.M.; Chien, J.W.; Eaton, K.D.; Goodman, M.T.; Tait, J.F.; Tewari, M.; Pritchard, C.C. Plasma processing conditions substantially influence circulating microrna biomarker levels. PLoS ONE 2013, 8, e64795. [Google Scholar] [CrossRef] [PubMed]
- Kirschner, M.B.; Kao, S.C.; Edelman, J.J.; Armstrong, N.J.; Vallely, M.P.; van Zandwijk, N.; Reid, G. Haemolysis during sample preparation alters microrna content of plasma. PLoS ONE 2011, 6, e24145. [Google Scholar] [CrossRef] [PubMed]
- Ballman, K.V. Biomarker: Predictive or prognostic? J. Clin. Oncol. 2015, 33, 3968–3971. [Google Scholar] [CrossRef] [PubMed]
miRNA | Effect | Sample | Disease Stage of CRC/Treatment | No of Patients | Outcome | Reference | |
---|---|---|---|---|---|---|---|
miR-21 | prognostic | Serum | Stage I to IV | 12 Discovery/ 182 Validation | High miR-21 levels associated with tumor size, distant metastasis, and poor survival | Toiyama [16] | |
miR-21 | prognostic | Plasma | Resectable | 57 Discovery/ No validation | High levels in plasma drawn from mesenteric vein correlated with shorter DFS | Monzo [20] | |
miR-21 | prognostic | Serum | Stage I to IV | 102 Discovery/ No validation | Low levels associated with short OS along with CEA, age and tumor stage | Menéndez [18] | |
miR-21, let-7g, miR-31, miR-92a, miR-181b, and miR-203 | prognostic | Serum | Localized or metastatic | 30 Discovery/ 83 Validation | The expression levels of the six serum miRNAs were correlated to tumor stage | Wang [23] | |
miR-26a, miR-124-5p | prognostic | Plasma | Unresectable or resectable | 71 Discovery/ No validation | High miR-124-5p and low miR-26a levels correlated with long OS | Jinushi [25] | |
miR-92a | prognostic | Serum | Resectable | 200 Discovery/ No validation | High levels associated with poor survival | Liu [17] | |
miR-141 | prognostic | Plasma | Stage IV | 102 Discovery/ 156 Validation | High levels were prognostic for short OS | Cheng [22] | |
miR-155 | prognostic | Serum | Localized or metastatic | 146 Discovery/ No validation | High levels correlated with OS and PFS | Lv [24] | |
miR-183 | prognostic | Plasma | Stage III and IV | 118 Discovery/No validation | High levels associated with local and distant recurrence and short DFS & OS | Yuan [32] | |
miR-200c | prognostic | Serum | Stage I to IV | 12 Discovery/ 182 Validation | Associated with local and distant recurrence. High level was prognostic for OS | Toiyama [21] | |
miR-221 | prognostic | Plasma | Stage I to IV | 103 Discovery/ No validation | High level was prognostic for short OS | Pu [19] | |
miR-19a | prognostic/potentially predictive | Serum | Stage IV/1st line FOLFOX | 16 Discovery/ 72 Validation | High levels in non-responders | Chen [26] | |
miR-20a, miR-130, miR-145, miR-216 and miR-372 | prognostic/potentially predictive | Serum | Stage III & IV/Oxilaplatin based chemotherapy | 253 Discovery/ No validation | Risk score analysis from all miRNAs predicts chemoresistance. | Zhang [27] | |
miR-106a, miR-484, and miR-130b (response), miR-27b, miR-148a, and miR-326 (PFS & OS) | prognostic/potentially predictive | Plasma | Stage IV/Nordic FLOX | 24 Discovery/ 150 Validation | High levels in non-responders. High levels associated with PFS. High miR-326 associated with short OS. | Kjersem [28] | |
miR-126 | prognostic/potentially predictive | Plasma | Stage IV/1st line chemotherapy + bevacizumab | 68 Discovery/ No validation | Changes during treatment separated responders vs. non-responders | Hansen [29] | |
miR-155, miR-200c, and miR-210 | prognostic/potentially predictive | Serum | Stage III/Different chemotherapy regimens with or without VEGF/EGFR inhibitors | 15 Discovery/ No validation | High levels predicting distant metastasis and chemoresistance | Chen [31] | |
miR-345, miR-143, miR-34*, miR-628-5p, miR-886-3p, miR-324-3p | prognostic/potentially predictive | Whole blood | Stage IV/3rd line irinotecan & cetuximab | 138 Discovery/ No validation | High levels prognostic for short OS | Schou & Rossi [30] |
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schou, J.V.; Johansen, J.S.; Nielsen, D.; Rossi, S. Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer. Non-Coding RNA 2016, 2, 5. https://doi.org/10.3390/ncrna2020005
Schou JV, Johansen JS, Nielsen D, Rossi S. Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer. Non-Coding RNA. 2016; 2(2):5. https://doi.org/10.3390/ncrna2020005
Chicago/Turabian StyleSchou, Jakob Vasehus, Julia Sidenius Johansen, Dorte Nielsen, and Simona Rossi. 2016. "Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer" Non-Coding RNA 2, no. 2: 5. https://doi.org/10.3390/ncrna2020005